San Antonio Breast Cancer Symposium | Conference

Dr. Lindeman on RANK Ligand as Breast Cancer Prevention Target in BRCA1 Carriers

December 8th 2016

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a study exploring RANK ligand as a target for breast cancer prevention in patients who harbor the BRCA1 mutation.

Dr. Kornblum on Impact of PrECOG 0102 Trial for HR+/HER2- Breast Cancer

December 8th 2016

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Six Years of Anastrozole After Adjuvant Tamoxifen Not Better Than 3 Years

December 8th 2016

First results from the phase III DATA study show no advantage to extending anastrozole therapy from 3 years to 6 for the primary endpoint of 5-year adapted disease-free survival.

Mixed Results on Benefit of Extending Letrozole Beyond 5 Years of Prior Endocrine Therapy

December 8th 2016

Extending letrozole therapy in women with early-stage, HR-positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival, but prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.

Genomic Study Uncovers Resistance Mutations in ER+ Breast Cancer

December 8th 2016

The genomic landscape of recurrent metastatic estrogen receptor–positive breast cancer differed significantly from the mutational profile of primary disease in a study that sheds light on acquired resistance mechanisms to anticancer therapies.

TILs Associated With Survival for Advanced HER2+ Breast Cancer

December 8th 2016

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer

December 8th 2016

Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.

Everolimus Added to Fulvestrant Doubles PFS in HR+ Breast Cancer

December 7th 2016

The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer

February 19th 2016

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.

Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast Cancer

January 28th 2016

Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

Dr. Blackwell on Margetuximab for HER2+ Breast Cancer

January 19th 2016

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast Cancer

January 18th 2016

Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.

Palbociclib Improves Cell Cycle Control in ER-Positive Breast Cancer

December 14th 2015

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

Pembrolizumab Continues to Show Promise in Breast Cancer

December 12th 2015

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

Neratinib DFS Benefit Sustained in 3-Year ExteNET Update

December 12th 2015

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

Dr. Patricia Ganz on Anastrozole versus Tamoxifen Side Effects in DCIS Patients

December 11th 2015

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.

IBIS-II: Anastrozole and Tamoxifen Similar on Recurrence, but Toxicity Profiles Differ

December 11th 2015

Breast cancer recurrence was similar whether postmenopausal women with ductal carcinoma in situ received anastrozole or tamoxifen for 5 years following local excision in the IBIS-II trial.

Tamoxifen or Anastrozole? Patient Reports Can Help Decide

December 11th 2015

Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.

NEXT PAGE
PREVIOUS PAGE